Skip to content

Consolidated statement of changes in equity

Download(XLS, 47 KB)
  Subscribed Capital Reserves
  Note Number of ordinary shares in thousand Amount € in thousands Amount € in millions Capital reserve € in millions Other reserves € in millions
As of December 31, 2019   557,380 557,380 557 3,989 12,422
Proceeds from the exercise of stock options 36 161 161 0 9  
Compensation expense related to stock options 36       -6  
Dividends paid 28         -468
Purchase of noncontrolling interests 27          
Share buy-back program of Fresenius Medical Care AG & Co. KGaA           -118
Put option liabilities 22, 32         -8
Comprehensive income (loss)            
Net income           1,707
Other comprehensive income (loss)            
Cash flow hedges 29, 32          
Change of FVOCI equity investments 29, 32          
Foreign currency translation 29, 32          
Actuarial gains on defined benefit pension plans 26, 29          
Fair value changes            
Comprehensive income (loss)           1,707
As of December 31, 2020   557,541 557,541 557 3,992 13,535
Proceeds from the exercise of stock options 36 961 961 1 33  
Compensation expense related to stock options 36       1  
Dividends paid 28         -491
Purchase of noncontrolling interests 27          
Put option liabilities 22, 32         -13
Transfer of cumulative gains / losses of equity investments           11
Comprehensive income (loss)            
Net income           1,818
Other comprehensive income (loss)            
Cash flow hedges 29, 32          
Change of FVOCI equity investments 29, 32          
Foreign currency translation 29, 32          
Actuarial gains / losses on defined benefit pension plans 26, 29          
Fair value changes            
Comprehensive income (loss)           1,818
As of December 31, 2021   558,502 558,502 558 4,026 14,860

Consolidated statement of changes in equity

Download(XLS, 39 KB)
  Accumulated other comprehensive income (loss)
  Foreign currency translation € in millions Cash flow hedges € in millions Pensions € in millions Equity investments € in millions Fair value changes € in millions Total Fresenius SE & Co. KGaA shareholders’ equity € in millions Noncontrolling interests € in millions Total shareholders’ equity € in millions
As of December 31, 2019 294 -65 -429 10 16,778 9,802 26,580
Proceeds from the exercise of stock options           9 9 18
Compensation expense related to stock options           -6 0 -6
Dividends paid           -468 -592 -1,060
Purchase of noncontrolling interests           28 28
Share buy-back program of Fresenius Medical Care AG & Co. KGaA           -118 -248 -366
Put option liabilities           -8 -17 -25
Comprehensive income (loss)                
Net income           1,707 1,116 2,823
Other comprehensive income (loss)                
Cash flow hedges   3       3 1 4
Change of FVOCI equity investments       -1   -1 4 3
Foreign currency translation -998   5     -993 -1,087 -2,080
Actuarial gains on defined benefit pension plans     19     19 2 21
Fair value changes         27 27 56 83
Comprehensive income (loss) -998 3 24 -1 27 762 92 854
As of December 31, 2020 -704 -62 -405 9 27 16,949 9,074 26,023
Proceeds from the exercise of stock options           34 4 38
Compensation expense related to stock options           1 1
Dividends paid           -491 -577 -1,068
Purchase of noncontrolling interests           98 98
Put option liabilities           -13 -27 -40
Transfer of cumulative gains / losses of equity investments       -11  
Comprehensive income (loss)                
Net income           1,818 1,001 2,819
Other comprehensive income (loss)                
Cash flow hedges   -4       -4 0 -4
Change of FVOCI equity investments       -40   -40 20 -20
Foreign currency translation 758 0 -7 0 1 752 727 1,479
Actuarial gains / losses on defined benefit pension plans     1     1 -8 -7
Fair value changes         -9 -9 -22 -31
Comprehensive income (loss) 758 -4 -6 -40 -8 2,518 1,718 4,236
As of December 31, 2021 54 -66 -411 -42 19 18,998 10,290 29,288
The following notes are an integral part of the consolidated financial statements.